BioPharma Dive April 17, 2024
Uwe Schoenbeck, who has more than 25 years of industry experience, is already heading up investment deals at the venture capital firm.
Dive Brief:
- Uwe Schoenbeck, a biotech veteran who most recently was chief scientific officer at Pfizer’s innovation division, has joined Canaan Partners as a venture partner, the investment firm announced Wednesday.
- Since starting at Canaan in January, Schoenbeck has led Canaan’s involvement in a $132 million Series B round for precision cancer drug developer Alterome Therapeutics.
- The firm also said Friday it has raised another $100 million to invest in technology and healthcare companies, bringing its total raised to more than $1 billion since launching a new fund in early 2023.
Dive Insight:
Canaan has been...
Today's Sponsors
Today's Sponsor